King's Research Portal

DOI:

[10.1016/j.soard.2017.05.024](https://doi.org/10.1016/j.soard.2017.05.024)

Document Version

Peer reviewed version

[Link to publication record in King's Research Portal](#)

Citation for published version (APA):

Risstad, H., Kristinsson, J. A., Fagerland, M. W., le Roux, C. W., Birkeland, K. I., Gulseth, H. L., Thorsby, P. M., Vincent, R. P., Engström, M., Olbers, T., & Mala, T. (2017). Bile acid profiles over 5 years following gastric bypass and duodenal switch – Results from a randomized clinical trial. *Surgery for obesity and related diseases*. <https://doi.org/10.1016/j.soard.2017.05.024>

Citing this paper

Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination, volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are again advised to check the publisher's website for any subsequent corrections.

General rights

Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the Research Portal

Take down policy

If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.

Author's Accepted Manuscript

Bile acid profiles over 5 years following gastric bypass and duodenal switch – Results from a randomized clinical trial

Hilde Risstad, Jon A. Kristinsson, Morten W. Fagerland, Carel W. le Roux, Kåre I. Birkeland, Hanne L. Gulseth, Per M. Thorsby, Royce P. Vincent, My Engström, Torsten Olbers, Tom Mala

PII: S1550-7289(17)30278-2
DOI: <http://dx.doi.org/10.1016/j.soard.2017.05.024>
Reference: SOARD3045

To appear in: *Surgery for Obesity and Related Diseases*

Cite this article as: Hilde Risstad, Jon A. Kristinsson, Morten W. Fagerland, Carel W. le Roux, Kåre I. Birkeland, Hanne L. Gulseth, Per M. Thorsby, Royce P. Vincent, My Engström, Torsten Olbers and Tom Mala, Bile acid profiles over 5 years following gastric bypass and duodenal switch – Results from a randomized clinical trial, *Surgery for Obesity and Related Diseases*, <http://dx.doi.org/10.1016/j.soard.2017.05.024>

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting galley proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Bile acid profiles over 5 years following gastric bypass and duodenal switch – results from a randomized clinical trial

Manuscript type: Original Contribution

Hilde Risstad, MD

Department of Endocrinology, Morbid Obesity and Preventive Medicine, Oslo University

Hospital, Oslo, Norway, and Institute of Clinical Medicine, University of Oslo, Oslo, Norway

hiriss@outlook.com

Jon A. Kristinsson, MD, PhD

Department of Endocrinology, Morbid Obesity and Preventive Medicine, Oslo University

Hospital, Oslo, Norway

joakri@ous-hf.no

Morten W. Fagerland, MSc, PhD

Oslo Centre for Biostatistics and Epidemiology, Research Support Services, Oslo University

Hospital, Oslo, Norway

morten.fagerland@medisin.uio.no

Carel W. le Roux, MD, PhD

Diabetes Complications Research Centre, Conway Institute, University College Dublin, Dublin, Ireland, and Department of Gastrosurgical Research, Sahlgrenska University Hospital, Gothenburg, Sweden
carel.leroux@ucd.ie

Kåre I. Birkeland, MD, PhD

Department of Endocrinology, Morbid Obesity and Preventive Medicine, Oslo University Hospital, Oslo, Norway, and Institute of Clinical Medicine, University of Oslo, Oslo, Norway
k.i.birkeland@medisin.uio.no

Hanne L. Gulseth, MD, PhD

Department of Endocrinology, Morbid Obesity and Preventive Medicine, Oslo University Hospital, Oslo, Norway, and Institute of Clinical Medicine, University of Oslo, Oslo, Norway
h.l.gulseth@medisin.uio.no

Per M. Thorsby, MD, PhD

Hormone Laboratory, Department of Medical Biochemistry, Oslo University Hospital, Oslo, Norway
pertho@ous-hf.no

Royce P. Vincent, MD

Department of Clinical Biochemistry (Viapath), King's College Hospital NHS Foundation Trust,

London, UK

royce.vincent@nhs.net

My Engström, PhD

Department of Gastrosurgical Research, Sahlgrenska University Hospital, Gothenburg, Sweden

my.engstrom@vgregion.se

Torsten Olbers, MD, PhD

Department of Gastrosurgical Research, Sahlgrenska University Hospital, Gothenburg, Sweden

torsten.olbers@gu.se

Tom Mala, MD, PhD

Department of Endocrinology, Morbid Obesity and Preventive Medicine, and Department of

Gastrointestinal Surgery, Oslo University Hospital, Oslo, Norway

tommal@ous-hf.no

Correspondence and requests for reprints:

Hilde Risstad

Oslo University Hospital

PO Box 4959, N-0424 Oslo, Norway

hiriss@outlook.com

Phone: +47 99 64 21 27

Source of Funding and Conflicts of Interest: This project was funded by a research fellowship from the South Eastern Norway Regional Health Authority (Dr Risstad). Additional grants were provided by the Norwegian Society for Gastroenterology (Dr Risstad). The funders had no role in the design and conduct of the study, preparation, review, or approval of the manuscript, and decision to submit the manuscript for publication. None of the authors report any financial or other activities for any aspect of the submitted work.

Mini abstract: Bile acids have been suggested as possible key mediators of the metabolic effects after bariatric surgery. With 5-year follow-up data from a randomized clinical trial, we compare bile acid profile after gastric bypass and duodenal switch, and explore the relationship between bile acids and weight loss, lipid profile and glucose metabolism.

Short running head: Bile acid profile after bariatric surgery

Acknowledgement: We thank the Norwegian Society for Gastroenterology for a research grant for this project.

Author contributions

Conception or design: Kristinsson, Olbers, Mala

Acquisition, analysis or interpretation of the data: All authors

Drafting the manuscript: Risstad

Revising the manuscript for critically for intellectual content: All authors

Statistical analysis: Risstad, Fagerland

Obtained funding: Risstad, Kristinsson, Olbers, Mala

Administrative, technical, or material support: le Roux, Gulseth, Thorsby, Engström, Vincent

Supervision: Olbers, Birkeland, Mala

Final approval of the version to be published: All authors

Abstract

Background: Bile acids have been proposed as key mediators of the metabolic effects after bariatric surgery. Currently no reports on bile acid profiles after duodenal switch exist, and long-term data after gastric bypass are lacking.

Objective: To investigate bile acid profiles up to 5 years after Roux-en-Y gastric bypass and biliopancreatic diversion with duodenal switch, and to explore the relationship between bile acids and weight loss, lipid profile and glucose metabolism.

Settings: Two Scandinavian University Hospitals.

Methods: We present data from a randomized, clinical trial of 60 patients with body mass index 50–60 kg/m² operated with gastric bypass or duodenal switch. Repeated measurements of total and individual bile acids from fasting serum during 5 years after surgery were performed.

Results: Mean concentrations of total bile acids increased from 2.3 µmol/L (95% CI, -0.1 to 4.7) at baseline to 5.9 µmol/L (3.5 to 8.3) 5 years after gastric bypass and from 1.0 µmol/L (95% CI, -1.4 to 3.5) to 9.5 µmol/L (95% CI, 7.1 to 11.9) after duodenal switch, mean between-group difference was -4.8 µmol/L (95% CI, -9.3 to -0.3), P=.036. Mean concentrations of primary bile acids increased more after duodenal switch, while secondary bile acids increased proportionally across the groups. Higher levels of total bile acids at 5 years were associated with lower body mass index, greater weight loss and lower total cholesterol.

Conclusions: Total bile acid concentrations increased substantially over 5 years after both gastric bypass and duodenal switch, with greater increases in total and primary bile acids after duodenal switch.

Keywords: Bariatric surgery; metabolic surgery; Roux-en-Y gastric bypass; gastric bypass, biliopancreatic diversion with duodenal switch; duodenal switch; randomized controlled trial; randomized clinical trial; bile acids, bile acid profiles

Introduction

Roux-en-Y gastric bypass (RYGB) and biliopancreatic diversion with duodenal switch (BPD/DS) provide considerable and durable weight loss and improve obesity-related diseases such as type 2 diabetes [1,2]. BPD/DS is more effective than RYGB to induce weight loss, improve glycemic control and lipid profiles [3-5]. The mechanisms of action for weight loss and metabolic improvements are complex and remain largely unknown.

Bile acids (BAs) participate in the control of glucose and lipid metabolism and energy homeostasis [6-8]. They act as signaling hormones by activating nuclear receptors and membrane coupled receptors in the intestine, liver, muscle and adipose tissue. Furthermore, they regulate the balance of different species of the microbiome, and the microbiome interacts reciprocally with the metabolism and composition of BAs [8,9]. BAs have been suggested as important mediators of weight loss and metabolic changes after bariatric surgery [10-13], and different fractions of BAs have been linked to different features of glucose metabolism [14,15]. Most studies report increased BA concentrations after RYGB [16,17], but studies exploring changes in BA fractions are inconsistent [18-20]. There are, to our knowledge, no reports of changes in BA profiles after BPD/DS, and there are no reports on BA profiles long term after bariatric surgery.

We used data from a randomized clinical trial to explore the effects of RYGB and BPD/DS on BA concentrations. We aimed to investigate the long term effect of the two procedures on total BA

concentrations and fractions, and to explore the relationship between BAs and measures of weight loss, blood lipids and glucose metabolism.

Methods

Study design

The rationale and design of our randomized clinical trial conducted at two Scandinavian University Hospitals has been reported previously [21]. Shortly, patients aged 20-50 years with body mass index (BMI, calculated as weight divided by height in meters squared) of 50-60 seeking bariatric surgery were randomized to receive RYGB or BPD/DS. The regional ethics committees approved the protocol, and all patients provided written consent. The trial was registered at clinicaltrials.gov Identifier NCT00327912.

The procedures were performed laparoscopically with standardized methodology [21]. In RYGB the alimentary limb was 150 cm and the biliopancreatic limb was 50 cm. In BPD/DS, the alimentary limb was 200 cm and the common channel was 100 cm. All patients with the gallbladder in situ were recommended daily oral intake of ursodeoxycholic acid (500 mg) for 6 months postoperatively as gall stone prophylaxis.

Results on weight loss, cardio-metabolic risk factors, nutritional status, adverse events, and patient-reported outcome measures have been reported previously [5,21-24]. The present report implements data from baseline, 1, 2 and 5 years.

Blood sample collection, laboratory analysis and calculations

Venous blood samples were obtained after an overnight fast at each study visit. Samples clotted 30 minutes at room temperature and serum was separated with centrifugation (1700 x g, 10 min) and aliquots were stored at -70°C in a biobank for later analyses.

Serum BA profile were analyzed with high performance liquid chromatography (JascoTM, USA) coupled to tandem mass spectrometry (Applied Biosystems, Cheshire, UK), in the Department of Clinical Biochemistry at the King's College Hospital NHS Foundation Trust in London, using established modifications of a previously described method [25]. The BAs quantified included 15 fractions. For individual BAs with values below the lowest area of detection we used a computer based method with imputation of a random value between 0 and the lowest area of detection. Composite concentrations of BAs were calculated by summing concentrations of individual BAs.

Statistics

The sample size was calculated for the primary end point of the study which was change in BMI between groups [21]. Because of the explorative nature of this substudy no power calculations were performed for the measures in this study. We used linear mixed model analyses to estimate mean changes in total and composite values of BA concentrations over time. The linear mixed models included fixed effects for procedure, time, and procedure x time interaction. Time was modelled as piecewise linear with two knots (1 and 2 years after surgery). A random intercept was used. Since cholecystectomy may influence BA concentrations and more patients

with BPD/DS had cholecystectomy, we performed sensitivity analyses on total BAs with samples obtained after cholecystectomy excluded. We also compared the composition of individual BAs and composite values between patients with and without cholecystectomy, and revealed a comparable pattern between the groups. Hence we decided to include all patients in the descriptive analyses.

For between group changes of individual BAs, we used linear regression with BA concentrations at 5 years as dependent variable and the baseline measurement and surgical procedure as independent variables. Although the distribution of the BA concentrations was slightly skewed, we found the difference in means to be a suitable effect measure, and that the distribution of the residuals from the linear regression models did not deviate much from the normal distribution.

To explore the relationship between total BA concentrations and measures of weight loss, lipid and glucose metabolism we used Spearman's rank order coefficient. A two-tailed $P < .05$ was considered statistically significant. Data were analyzed with Stata 14 College Station, TX (StataCorp LP) and IBM SPSS Statistics for Windows, version 24, Armonk, NY (IBM Corporation).

Results

Patient characteristics are described in Table 1. Before surgery, 18% of the patients had type 2 diabetes, and all of these patients experienced partial or complete remission 5 years after surgery. At 1, 2 and 5 years, 1 (1.7%), 2 (3.3%) and 5 (8.3%) of the patients were lost to follow-up, respectively. Five patients (3 RYGB and 2 BPD/DS) had cholecystectomy before study inclusion. Additional 6 patients (1 RYGB and 5 BPD/DS) had cholecystectomy during the study. As previously reported, patients with BPD/DS had substantially greater BMI and weight loss compared to RYGB patients, corresponding to a difference of 24.9 kg or 8.5 kg/m² between groups[5].

Total and composite values of BAs are presented in Table 2 and show that total bile acid concentrations increased significantly more after BPD/DS compared to RYGB. We observed large intra- and inter-variability of total BAs after both procedures, and the variability tended to increase after surgery (Figure 1).

At 5 years, patients with cholecystectomy had higher concentrations of total BAs than patients without cholecystectomy; mean 19.7 µmol/L (10.6 to 28.8) vs 4.6 µmol/L (95% CI, 3.2 to 5.9), $P < .001$ (Figure 1). We therefore did sensitivity analysis with only patients with the gall bladder in situ included (Table 2).

The concentrations of individual BAs are shown in Table 3. The larger increase in total BA concentrations after BPD/DS compared to RYGB was primarily driven by greater increases in

primary BAs, predominantly the unconjugated primary BAs cholic and chenodeoxycholic acid and their glycine-conjugates (Table 2 and 3). The concentrations of secondary BAs increased after surgery in both groups, with no between-group difference. The composition of BAs changed differently, with an increase in the proportion of primary BAs after BPD/DS and an increase in the proportion of secondary BAs after RYGB (Table 1).

The ratio of the 12 α -hydroxylated / non-12 α -hydroxylated BAs increased from 0.8 (95% CI, 0.6 to 1.0) at baseline to 1.1 (95% CI, 0.9 to 1.3) 5 years after RYGB ($P=.04$) and from 0.7 (95% CI, 0.6 to 0.9) to 1.3 (1.0 to 1.5) after BPD/DS ($P<.001$). Mean between group difference was 0.2 (95% CI, -0.1 to 0.5); $P=.21$.

At 5 years, higher levels of fasting total BA concentrations were associated with lower BMI and measures of weight loss (Table 4). We also observed an inverse correlation between total BAs and total cholesterol. Changes in total levels of BA concentrations between baseline and 5 years correlated significantly with weight loss.

Discussion

In this study of BA profiles during 5 years of RYGB and BPD/DS, we observed substantial increase in the fasting serum concentrations after both procedures, with greater increase in total BA concentrations after BPD/DS compared to RYGB. The composition of BAs changed differently across the groups.

Several other studies have investigated BA concentrations after RYGB. Most short-term studies (< 2 months after surgery) report unchanged or decreased levels of total BAs [26-28], while most studies reporting data from several months and years after surgery report increased concentrations [18,20,29-32]. Our findings are in accordance with the existent literature, and extend the current knowledge by showing that the BA levels apparently continue to increase up to 5 years after RYGB. Changes in BAs after BPD/DS have not previously been explored.

Interestingly, in a model of duodenal-jejunal bypass with short and long biliopancreatic limbs, increased BA concentrations were observed in rats with long biliopancreatic limb, together with suppression of weight gain and improved glucose metabolism [33]. This experimental study supports that a long biliopancreatic limb may be important for the metabolic improvements after bariatric surgery and suggests that BAs play a role, but the causal relationship between BAs and the metabolic improvements is still uncertain.

The mechanisms for the higher BA concentrations after BPD/DS compared to RYGB are unknown, and can arise through several mechanisms. Differences in intestinal absorption may contribute. The longer biliopancreatic limb in BPD/DS leads to transportation of high

concentrations of primary BAs through a longer segment of the small bowel before they mix with food and promote fat digestion and absorption in the common channel, and could therefore be more available for absorption. We found that the higher concentrations of primary BAs after BPD/DS were predominantly due to increases in the unconjugated and glycine-conjugated primary BAs. In normal anatomy, BAs in the upper intestine are dominated by primary conjugated BAs [34]. One possible explanation for the rise in unconjugated BAs could be that microbial contamination of the small intestine due to altered gut anatomy causes bacterial deconjugation of BAs and subsequently absorption in the biliopancreatic limb [34-36]. This could mean that the great elevation of BAs that we observe after BPD/DS (and also RYGB) not necessarily reflects an actual increase in the size of the bile salt pool, but could rather be a result of shorter enterohepatic cycling.

The repeated measurements in our study revealed that BAs continued to increase years after surgery. Changed microbial metabolism may be involved as they can modulate the BA pool [37]. Changes in BA synthesis or excretion could also be involved [38]. Cholesterol is an essential constituent of BAs. Our finding of an inverse correlation between total BAs and total cholesterol, together with a greater reduction in total cholesterol, LDL cholesterol and triglycerides after BPD/DS compared to RYGB in the main study, leads us to speculate that increased hepatic production and/or increased fecal excretion of BAs contribute to our observations.

We found significantly higher serum BA levels in patients with cholecystectomy compared to patients with the gall bladder in situ 5 years after surgery. This may, completely or partly, be

attributable to increased cycling of the BA pool in the enterohepatic circulation due to lack of storage capacity [39,40].

We observed a relationship between higher total BA concentrations at 5 years and lower BMI, greater weight loss and lower serum total cholesterol. These observations must be considered as explorative and no conclusions about a causal relationship between these variables and bile acid concentrations can be done. As in several other studies, we were not able to demonstrate any correlation between BAs and markers of glucose metabolism and insulin resistance [18,20,27,28]. We found large variations in fasting BA concentrations both within and between individuals, as depicted in Figure 1. This is in line with studies of non-bariatric subjects, which found large diurnal variations within individuals [41,42] and large variations in production and concentrations between individuals [43,44].

Insulin regulates BA composition, in part by regulating the BA 12- α hydroxylase (CYP8B1), and it has been shown that a high ratio of 12 α -hydroxylated / non-12 α -hydroxylated BAs is associated with more insulin resistance [14]. A study of patients with type 2 diabetes observed, contrary to their hypothesis, an increase in this ratio after RYGB [28]. Our study, which mostly included non-diabetic subjects, also demonstrated an increased ratio after both procedures at 5 years.

Strengths of this study include the randomized design with a well-defined patient population, close to complete follow-up at all time points, and standardized surgical procedures. BA composition was carefully characterized at several time points and includes long-term

evaluation. Limitations include measurements of BAs in peripheral blood. We did not measure post-prandial BA responses, markers of production, fecal excretion, enteric hormones or fecal microbiome, which would have helped us to better understand the physiological changes that underlie our findings. The findings of this study may not generalize to patients outside the BMI and age restriction in our study, and probably of more importance, to patients with type 2 diabetes or severe metabolic disease. Previous studies have shown different bile acid profiles and responses in subjects with type 2 diabetes compared to non-diabetic subjects both before and after bariatric surgery [11,45].

We have demonstrated larger increases in serum BAs and a different change in bile acid species and composition after BPD/DS than after RYGB. Whether there is a causal relationship between the higher increase in BAs after BPD/DS and the superior metabolic effects compared to RYGB remains unknown. Our findings of a relationship between BAs and measures of weight and weight loss and total cholesterol may suggest that BAs play a role in the metabolic improvements after the two procedures, but a causal relationship is still unknown. Other mechanisms are involved, and isolating the effect of changes in the enterohepatic circulations of BAs has not been achieved. Further mechanistic studies are warranted to reveal the physiology of altered BA concentrations after bariatric surgery, and to investigate the possible impact of BAs on the metabolic improvements. Measures from patients with normal gut anatomy have shown large variability in the BA concentrations within and between individuals, and our study implicates that this variability fluctuates even more after RYGB and BPD/DS. This, and the fact

that cholecystectomy may result in a substantial change in the enterohepatic circulation, should be taken into account in the planning of future studies.

Conclusions

Fasting serum concentrations of total BAs increased substantially over 5 years after both RYGB and BPD/DS. Patients undergoing BPD/DS had greater increase in total and primary BAs in comparison to RYGB. At 5 years, there was a positive correlation between total BA concentration and weight loss, and an inverse correlation between total BA concentrations and BMI and total cholesterol.

Acknowledgement

We thank the Norwegian Society for Gastroenterology for a research grant for this project.

References

- [1] Puzziferri N, Roshek TB, 3rd, Mayo HG, et al. Long-term follow-up after bariatric surgery: a systematic review. *Jama*. 2014;312:934-42.
- [2] Mingrone G, Panunzi S, De Gaetano A, et al. Bariatric-metabolic surgery versus conventional medical treatment in obese patients with type 2 diabetes: 5 year follow-up of an open-label, single-centre, randomised controlled trial. *Lancet*. 2015;386:964-73.
- [3] Hedberg J, Sundstrom J, Sundbom M. Duodenal switch versus Roux-en-Y gastric bypass for morbid obesity: systematic review and meta-analysis of weight results, diabetes resolution and early complications in single-centre comparisons. *Obes Rev*. 2014;15:555-63.
- [4] Buchwald H, Estok R, Fahrbach K, et al. Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis. *Am J Med*. 2009;122:248-56.
- [5] Risstad H, Sovik TT, Engstrom M, et al. Five-year outcomes after laparoscopic gastric bypass and laparoscopic duodenal switch in patients with body mass index of 50 to 60: a randomized clinical trial. *JAMA Surg*. 2015;150:352-61.
- [6] Zhou H, Hylemon PB. Bile acids are nutrient signaling hormones. *Steroids*. 2014;86:62-8.
- [7] Zhang Y, Lee FY, Barrera G, et al. Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice. *Proc Natl Acad Sci U S A*. 2006;103:1006-11.

- [8] Watanabe M, Houten SM, Matakaki C, et al. Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation. *Nature*. 2006;439:484-9.
- [9] Ridlon JM, Kang DJ, Hylemon PB. Bile salt biotransformations by human intestinal bacteria. *J Lipid Res*. 2006;47:241-59.
- [10] Kohli R, Seeley RJ. Diabetes: the search for mechanisms underlying bariatric surgery. *Nat Rev Endocrinol*. 2013;9:572-4.
- [11] Gerhard GS, Styer AM, Wood GC, et al. A role for fibroblast growth factor 19 and bile acids in diabetes remission after Roux-en-Y gastric bypass. *Diabetes Care*. 2013;36:1859-64.
- [12] Ryan KK, Tremaroli V, Clemmensen C, et al. FXR is a molecular target for the effects of vertical sleeve gastrectomy. *Nature*. 2014;509:183-8.
- [13] Madsbad S, Dirksen C, Holst JJ. Mechanisms of changes in glucose metabolism and bodyweight after bariatric surgery. *Lancet Diabetes Endocrinol*. 2014;2:152-64.
- [14] Haeusler RA, Astiarraga B, Camastra S, et al. Human insulin resistance is associated with increased plasma levels of 12alpha-hydroxylated bile acids. *Diabetes*. 2013;62:4184-91.
- [15] Wewalka M, Patti ME, Barbato C, et al. Fasting serum taurine-conjugated bile acids are elevated in type 2 diabetes and do not change with intensification of insulin. *J Clin Endocrinol Metab*. 2014;99:1442-51.
- [16] Cole AJ, Teigen LM, Jahansouza C, et al. The Influence of Bariatric Surgery on Serum Bile Acids in Humans and Potential Metabolic and Hormonal Implications: a Systematic Review. *Curr Obes Rep*. 2015;4:441-50.
- [17] Fouladi F, Mitchell JE, Wonderlich JA, et al. The Contributing Role of Bile Acids to Metabolic Improvements After Obesity and Metabolic Surgery. *Obes Surg*. 2016;26:2492-502.
- [18] Kohli R, Bradley D, Setchell KD, et al. Weight loss induced by Roux-en-Y gastric bypass but not laparoscopic adjustable gastric banding increases circulating bile acids. *J Clin Endocrinol Metab*. 2013;98:E708-12.
- [19] Dutia R, Embrey M, O'Brien CS, et al. Temporal changes in bile acid levels and 12alpha-hydroxylation after Roux-en-Y gastric bypass surgery in type 2 diabetes. *Int J Obes (Lond)*. 2015;39:806-13.
- [20] Simonen M, Dali-Youcef N, Kaminska D, et al. Conjugated bile acids associate with altered rates of glucose and lipid oxidation after Roux-en-Y gastric bypass. *Obes Surg*. 2012;22:1473-80.
- [21] Sovik TT, Taha O, Aasheim ET, et al. Randomized clinical trial of laparoscopic gastric bypass versus laparoscopic duodenal switch for superobesity. *Br J Surg*. 2010;97:160-6.
- [22] Sovik TT, Aasheim ET, Taha O, et al. Weight loss, cardiovascular risk factors, and quality of life after gastric bypass and duodenal switch: a randomized trial. *Ann Intern Med*. 2011;155:281-91.
- [23] Aasheim ET, Bjorkman S, Sovik TT, et al. Vitamin status after bariatric surgery: a randomized study of gastric bypass and duodenal switch. *Am J Clin Nutr*. 2009;90:15-22.
- [24] Sovik TT, Karlsson J, Aasheim ET, et al. Gastrointestinal function and eating behavior after gastric bypass and duodenal switch. *Surg Obes Relat Dis*. 2012.
- [25] Tagliacozzi D, Mozzi AF, Casetta B, et al. Quantitative analysis of bile acids in human plasma by liquid chromatography-electrospray tandem mass spectrometry: a simple and rapid one-step method. *Clin Chem Lab Med*. 2003;41:1633-41.
- [26] Steinert RE, Peterli R, Keller S, et al. Bile acids and gut peptide secretion after bariatric surgery: a 1-year prospective randomized pilot trial. *Obesity (Silver Spring)*. 2013;21:E660-8.
- [27] Jorgensen NB, Jacobsen SH, Dirksen C, et al. Acute and long-term effects of Roux-en-Y gastric bypass on glucose metabolism in subjects with Type 2 diabetes and normal glucose tolerance. *Am J Physiol Endocrinol Metab*. 2012;303:E122-31.
- [28] Dutia R, Embrey M, O'Brien CS, et al. Temporal changes in bile acid levels and 12alpha-hydroxylation after Roux-en-Y gastric bypass surgery in type 2 diabetes. *Int J Obes (Lond)*. 2015.

- [29] Patti ME, Houten SM, Bianco AC, et al. Serum bile acids are higher in humans with prior gastric bypass: potential contribution to improved glucose and lipid metabolism. *Obesity (Silver Spring)*. 2009;17:1671-7.
- [30] Werling M, Vincent RP, Cross GF, et al. Enhanced fasting and post-prandial plasma bile acid responses after Roux-en-Y gastric bypass surgery. *Scand J Gastroenterol*. 2013;48:1257-64.
- [31] Jorgensen NB, Dirksen C, Bojsen-Moller KN, et al. Improvements in glucose metabolism early after gastric bypass surgery are not explained by increases in total bile acids and fibroblast growth factor 19 concentrations. *J Clin Endocrinol Metab*. 2015;100:E396-406.
- [32] Pournaras DJ, Glicksman C, Vincent RP, et al. The role of bile after Roux-en-Y gastric bypass in promoting weight loss and improving glycaemic control. *Endocrinology*. 2012;153:3613-9.
- [33] Miyachi T, Nagao M, Shibata C, et al. Biliopancreatic limb plays an important role in metabolic improvement after duodenal-jejunal bypass in a rat model of diabetes. *Surgery*. 2016;159:1360-71.
- [34] Dietschy JM. Mechanisms for the intestinal absorption of bile acids. *J Lipid Res*. 1968;9:297-309.
- [35] Picard M, Frederic Simon H, Stefane L, et al. Complications of combined gastric restrictive and malabsorptive procedures: part 2. *Curr Surg*. 2003;60:274-9; discussion 79-81.
- [36] Tabaqchali S, Hatzioannou J, Booth CC. Bile-salt deconjugation and steatorrhoea in patients with the stagnant-loop syndrome. *Lancet*. 1968;2:12-6.
- [37] Ridlon JM, Kang DJ, Hylemon PB, et al. Bile acids and the gut microbiome. *Curr Opin Gastroenterol*. 2014;30:332-8.
- [38] Ferrannini E, Camastra S, Astiarraga B, et al. Increased Bile Acid Synthesis and Deconjugation After Biliopancreatic Diversion. *Diabetes*. 2015;64:3377-85.
- [39] Shaffer EA, Small DM. Biliary lipid secretion in cholesterol gallstone disease. The effect of cholecystectomy and obesity. *J Clin Invest*. 1977;59:828-40.
- [40] Escalona A, Munoz R, Irribarra V, et al. Bile acids synthesis decreases after laparoscopic sleeve gastrectomy. *Surg Obes Relat Dis*. 2016;12:763-9.
- [41] Steiner C, Othman A, Saely CH, et al. Bile acid metabolites in serum: intraindividual variation and associations with coronary heart disease, metabolic syndrome and diabetes mellitus. *PLoS One*. 2011;6:e25006.
- [42] Galman C, Angelin B, Rudling M. Bile acid synthesis in humans has a rapid diurnal variation that is asynchronous with cholesterol synthesis. *Gastroenterology*. 2005;129:1445-53.
- [43] Galman C, Angelin B, Rudling M. Pronounced variation in bile acid synthesis in humans is related to gender, hypertriglyceridaemia and circulating levels of fibroblast growth factor 19. *J Intern Med*. 2011;270:580-8.
- [44] Xie G, Wang Y, Wang X, et al. Profiling of Serum Bile Acids in a Healthy Chinese Population Using UPLC-MS/MS. *J Proteome Res*. 2015;14:850-9.
- [45] Vincent RP, Omar S, Ghozlan S, et al. Higher circulating bile acid concentrations in obese patients with type 2 diabetes. *Ann Clin Biochem*. 2013;50:360-4.

Table 1. Baseline and 5-year data by treatment group

Variable	RYGB (n=31)	BPD/DS (n=29)
Age at inclusion, years	35.2 (7.0)	36.1 (5.3)
Female, n (%)	23 (74.2)	19 (65.5)
White, n (%)	30 (96.8)	27 (93.1)
Body weight, kg		
Baseline	162.1 (24.1)	162.2 (19.7)
5 y change from baseline	-42.8 (21.6)	-66.5 (23.3)
BMI (kg/m²)		
Baseline	54.8 (3.2)	55.2 (3.5)
5 y change from baseline	-13.1 (7.3)	-20.4 (7.1)
Total cholesterol, mg/dL		
Baseline	186 (34)	186 (26)
5 y change from baseline	-7 (29)	-53 (23)
LDL-C, mg/dL		
Baseline	110 (25)	110 (24)
5 y change from baseline	-10 (25)	-40 (24)
HDL-C, mg/dL		
Baseline	46 (10)	45 (10)
5 y change from baseline	17 (12)	7 (10)
Triglycerides, mg/dL		
Baseline	147 (75)	160 (59)
5 y change from baseline	-62 (61)	-86 (51)
Glucose, mg/dL		
Baseline	110 (31)	114 (38)
5 y change from baseline	-10 (28)	-27 (42)
Cholecystectomy, n (%)		
Baseline	3 (9.7)	2 (6.9)
5 y	4 (12.9)	7 (24.1)
Type 2 diabetes, n (%)		
Baseline	5 (16.1)	6 (20.7)
5 y	0	0
Use of glucose-lowering medication, n (%)		
Baseline	3 (9.7)	2 (6.9)
5 y	0	0
Hypertension, n (%)		
Baseline	8 (25.8)	8 (27.6)
5 y	4 (14.8)	7 (25.0)
Metabolic syndrome, n (%)		
Baseline	20 (64.5)	23 (79.3)
5 y	3 (11.1)	1 (3.6)

Abbreviations: RYGB, Roux-en-Y gastric bypass; BPD/DS, biliopancreatic diversion with duodenal switch; y, years; BMI, body mass index; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol.
Mean (SD) are reported for continuous variables.

Table 2. Composite measures of bile acid concentrations after RYGB and BPD/DS up to 5 years after surgery

Bile acids		Mean concentrations (95% CI)	Mean change (5y-B) within group (95% CI); P value	Mean change between groups (5y-B); P value
Total, $\mu\text{mol/L}$				
Preop	RYGB	2.3 (-0.1, 4.7)	3.6 (0.5, 6.8); P=.025 8.5 (5.3, 11.6); P<.001	-4.8 (-9.3, -0.3); P=.036
	BPD/DS	1.0 (-1.4, 3.5)		
1 y	RYGB	2.5 (0.1, 5.0)		
	BPD/DS	6.4 (3.9, 9.0)		
2 y	RYGB	4.7 (2.3, 7.1)		
	BPD/DS	8.2 (5.6, 10.8)		
5 y	RYGB	5.9 (3.5, 8.3)		
	BPD/DS	9.5 (7.1, 11.9)		
Glycine conjugated, $\mu\text{mol/L}$				
Preop	RYGB	1.2 (-0.3, 2.7)	1.7 (-0.2, 3.7); P=.08 4.2 (2.2, 6.1); P<.001	-2.4 (-5.2, 0.3); P=.09
	BPD/DS	0.6 (-1.0, 2.1)		
1 y	RYGB	1.2 (-0.3, 2.8)		
	BPD/DS	2.8 (1.2, 4.4)		
2 y	RYGB	1.7 (0.2, 3.1)		
	BPD/DS	3.5 (1.9, 5.1)		
5 y	RYGB	3.0 (1.5, 4.5)		
	BPD/DS	4.7 (3.3, 6.2)		
Taurine conjugated, $\mu\text{mol/L}$				
Preop	RYGB	0.14 (0.02, 0.27)	0.2 (0.009, 0.3); P=.37 0.1 (-0.1, 0.2); P=.26	0.1 (-0.1, 0.3); P=.50
	BPD/DS	0.001 (-0.12, 0.13)		
1 y	RYGB	0.1 (-0.008, 0.2)		
	BPD/DS	0.1 (-0.02, 0.2)		
2 y	RYGB	0.1 (-0.004, 0.2)		
	BPD/DS	0.1 (-0.01, 0.3)		
5 y	RYGB	0.2 (0.009, 0.3)		
	BPD/DS	0.1 (-0.1, 0.2)		
Total unconjugated, $\mu\text{mol/L}$				
Preop	RYGB	0.9 (-0.6, 2.5)	1.7 (-0.3, 3.7); P=.09	-2.5 (-5.3, 0.3); P=.09

	BPD/DS	0.5 (-1.1, 2.0)	4.2 (2.2, 6.2); P<.001	
1 y	RYGB	1.2 (-0.4, 2.7)		
	BPD/DS	3.5 (1.9, 5.1)		
2 y	RYGB	2.9 (1.4, 4.4)		
	BPD/DS	4.6 (3.0, 6.3)		
5 y	RYGB	2.7 (1.2, 4.2)		
	BPD/DS	4.7 (3.2, 6.2)		
Proportion Conjugated, %				
Preop	RYGB	64.8 (54.0, 75.5)	-12.9 (-26.9, 1.0); P=.07	6.9 (-12.7, 26.5);P=.49
	BPD/DS	54.9 (44.0, 65.8)	-19.8 (-33.6, -6.0); P=.005	
1 y	RYGB	54.3 (43.5, 65.0)		
	BPD/DS	47.3 (36.3, 58.2)		
2 y	RYGB	57.5 (47.1, 67.9)		
	BPD/DS	42.2 (31.1, 53.4)		
5 y	RYGB	51.8 (41.3, 62.3)		
	BPD/DS	35.1 (24.9, 45.3)		
Proportion unconjugated, %				
Preop	RYGB	35.2 (24.5, 46.0)	12.9 (-1.0, 26.9); P=.07	-6.9 (-26.5, 12.7); P=.49
	BPD/DS	45.1 (34.2, 56.0)	19.8 (6.0, 33.6); P=.005	
1 y	RYGB	45.7 (35.0, 56.5)		
	BPD/DS	52.7 (41.8, 63.7)		
2 y	RYGB	42.5 (32.1, 52.9)		
	BPD/DS	57.8 (46.6, 68.9)		
5 y	RYGB	48.2 (37.7, 58.7)		
	BPD/DS	64.9 (54.7, 75.1)		
Primary, μmol/L				
Preop	RYGB	1.6 (-0.3, 3.4)	2.4 (-0.1, 4.8); P=.06	-4.3 (-7.8, -0.9); P=.015
	BPD/DS	0.7 (-1.2, 2.6)	6.7 (4.2, 9.1); P<.001	

1 y	RYGB	1.7 (-0.2, 3.6)		
	BPD/DS	4.9 (3.0, 6.9)		
2 y	RYGB	3.4 (1.6, 5.2)		
	BPD/DS	5.8 (3.8, 7.8)		
5 y	RYGB	4.0 (2.1, 5.8)		
	BPD/DS	7.4 (5.6, 9.2)		
Secondary, $\mu\text{mol/L}$				
Preop	RYGB	0.7 (-0.03, 1.4)	1.3 (0.3, 2.2); P=.01	-0.5 (-1.9, 0.9); P=.47
	BPD/DS	0.4 (-0.4, 1.1)	1.8 (0.8, 2.7); P<.001	
1 y	RYGB	0.8 (0.1, 1.6)		
	BPD/DS	1.5 (0.7, 2.3)		
2 y	RYGB	1.3 (0.5, 2.0)		
	BPD/DS	2.4 (1.6, 3.2)		
5 y	RYGB	2.0 (1.2, 2.7)		
	BPD/DS	2.1 (1.4, 2.9)		
Proportion Primary, %				
Preop	RYGB	69.0 (61.7, 76.3)	-12.2 (-21.7, -2.6); P=.012	-28.4 (-41.8, -15.0); P<.001
	BPD/DS	56.9 (49.5, 64.3)	16.3 (6.9, 25.7); P<.001	
1 y	RYGB	62.5 (55.2, 69.8)		
	BPD/DS	69.3 (61.8, 76.8)		
2 y	RYGB	64.6 (57.5, 71.7)		
	BPD/DS	75.2 (67.6, 82.8)		
5 y	RYGB	56.9 (50.0, 64.0)		
	BPD/DS	73.2 (66.2, 80.1)		
Proportion secondary, %				
Preop	RYGB	31.0 (23.7, 38.3)	12.2 (2.6, 21.7); P=.012	28.4 (15.0, 41.8); P<.001
	BPD/DS	43.1 (35.7, 50.4)	-16.3 (-25.7, -6.9); P<.001	
1 y	RYGB	37.5 (30.2, 44.8)		
	BPD/DS	30.7 (23.2, 38.2)		
2 y	RYGB	35.4 (28.3, 42.5)		
	BPD/DS	24.8 (17.2,		

5 y	RYGB	32.4) 43.1 (36.0, 50.3)		
	BPD/DS	26.8 (19.9, 33.8)		
Total, cholecystectomy excluded^a				
Preop	RYGB	2.1 (0.3, 3.9)	1.4 (-1.0, 3.7); P=.26	-3.4 (-6.8, -0.4); P=.048
	BPD/DS	1.1 (-0.8, 2.9)	4.8 (2.4, 7.2); P<.001	
1 y	RYGB	2.5 (0.7, 4.3)		
	BPD/DS	6.1 (4.2, 8.0)		
2 y	RYGB	3.7 (1.9, 5.5)		
	BPD/DS	6.5 (4.6, 8.5)		
5 y	RYGB	3.5 (1.6, 5.3)		
	BPD/DS	5.9 (4.0, 7.8)		

Abbreviations: RYGB, Roux-en-Y gastric bypass; BPD/DS, biliopancreatic diversion with duodenal switch; Preop, preoperatively.

^aSensitivity analyses with bile acid concentration measures obtained after patients with cholecystectomy (n=11) excluded.

Table 3. Individual bile acid concentrations and fractions before and 5 years after RYGB and BPD/DS

	Procedure	Preop	5 y	Mean between- group change ^a	P value ^a
Primary unconjugated bile acids					
CA					
μmol/L, mean (95% CI)	RYGB	0.22 (0.07, 0.39)	0.70 (- 0.13, 1.53)	0.84 (-0.36, 2.04)	.16
	BPD/DS	0.06 (0.03, 0.09)	1.63 (0.82, 2.46)		
% TBA, mean (95% CI)	RYGB	7.1 (3.7, 10.4)	8.0 (4.0, 12.1)	10.2 (2.9, 17.4)	.007
	BPD/DS	4.0 (2.3, 5.6)	18.7 (12.8, 24.6)		

CDCA					
μmol/L, mean (95% CI)	RYGB	0.26 (0.11, 0.40)	1.03 (- 0.19, 2.25)	0.18 (-1.17, 1.52)	.79
	BPD/DS	0.12 (0.07, 0.17)	1.37 (0.85, 1.89)		
% TBA, mean (95% CI)	RYGB	9.1 (5.7, 12.6)	10.3 (5.0, 15.7)	7.1 (0.4, 13.9)	.039
	BPD/DS	7.9 (5.4, 10.4)	17.6 (13.3, 21.9)		
Primary conjugated bile acids					
GCA					
μmol/L, mean (95% CI)	RYGB	0.19 (0.11, 0.28)	0.32 (0.17, 0.47)	0.91 (-0.02, 1.83)	.05
	BPD/DS	0.12 (0.08, 0.16)	1.26 (0.36, 2.16)		
% TBA, mean (95% CI)	RYGB	7.9 (5.7, 10.1)	7.6 (5.4, 9.7)	0.7 (-3.0, 4.5)	.69
	BPD/DS	7.3 (5.7, 8.9)	8.3 (5.1, 11.4)		
TCA					
μmol/L, mean (95% CI)	RYGB	0.04 (0.01, 0.07)	0.05 (0.03, 0.07)	0.001 (- 0.03, 0.03)	.93
	BPD/DS	0.03 (0.02, 0.03)	0.05 (0.02, 0.07)		
% TBA, mean (95% CI)	RYGB	1.4 (0.7, 2.1)	2.2 (1.1, 3.3)	-0.02 (- 0.04, 0.01)	.28
	BPD/DS	2.0 (1.5, 5.6)	0.8 (0.4, 1.2)		
GCDCA					
μmol/L, mean (95% CI)	RYGB	0.65 (0.44, 0.85)	1.04 (0.59, 1.50)	1.49 (-0.57, 3.04)	.15
	BPD/DS	0.39 (0.27, 0.51)	2.73 (0.79, 4.67)		
% TBA, mean (95% CI)	RYGB	28.2 (24.2, 32.2)	24.1 (18.0, 30.1)	-7.4 (-15.8, 1.0)	.08

	BPD/DS	24.1 (19.7, 28.5)	19.3 (12.3, 26.2)		
TCDC					
μmol/L, mean (95% CI)	RYGB	0.06 (0.03, 0.09)	0.10 (0.05, 0.14)		
	BPD/DS	0.04 (0.03, 0.05)	0.07 (0.04, 0.10)		
% TBA, mean (95% CI)	RYGB	3.0 (2.1, 3.9)	2.8 (1.6, 4.1)	-1.7 (-3.0, -0.5)	.009
	BPD/DS	2.8 (1.9, 3.7)	1.1 (0.6, 1.6)		
Secondary unconjugated bile acids					
DCA					
μmol/L, mean (95% CI)	RYGB	0.3 (0.1, 0.4)	0.8 (0.3, 1.3)	0.12 (-0.43, 0.66)	.67
	BPD/DS	0.2 (0.2, 0.3)	0.9 (0.6, 1.2)		
% TBA, mean (95% CI)	RYGB	11.3 (7.8, 14.8)	16.0 (12.5, 19.4)	-1.3 (-7.7, 5.1)	.68
	BPD/DS	14.8 (11.5, 18.1)	15.5 (10.0, 20.9)		
UDCA					
μmol/L, mean (95% CI)	RYGB	0.06 (0.04, 0.08)	0.09 (0.01, 0.17)	0.02 (-0.07, 0.10)	.74
	BPD/DS	0.05 (0.03, 0.06)	0.10 (0.06, 0.14)		
% TBA, mean (95% CI)	RYGB	3.2 (2.3, 4.1)	1.8 (1.2, 2.3)	0.3 (-0.7, 1.3)	.55
	BPD/DS	3.1 (2.3, 4.0)	2.1 (1.1, 3.0)		
LCA					
μmol/L, mean (95% CI)	RYGB	0.07 (0.06, 0.09)	0.07 (0.06, 0.09)	0.01 (-0.02, 0.31)	.51
	BPD/DS	0.07 (0.05, 0.09)	0.08 (0.07, 0.10)		
% TBA, mean	RYGB	4.5 (2.9, 6.1)	3.8 (2.0, 5.6)	-1.9 (-4.0, 0.2)	.08

(95% CI)			5.6)	0.2)
	BPD/DS	5.6 (3.6, 7.6)	2.0 (0.8, 3.2)	
Secondary conjugated bile acids				
GDCA				
μmol/L, mean (95% CI)	RYGB	0.2 (0.1, 0.3)	0.5 (0.3, 0.6)	0.34 (-0.38, 1.05) .34
	BPD/DS	0.1 (0.1, 0.2)	0.8 (0.1, 1.5)	
% TBA, mean (95% CI)	RYGB	8.5 (6.5, 10.4)	11.9 (9.1, 14.7)	-5.2 (-8.7, -1.7) .005
	BPD/DS	8.1 (5.8, 10.5)	6.7 (4.5, 9.0)	
TDCA				
μmol/L, mean (95% CI)	RYGB	0.04 (0.03, 0.05)	0.07 (0.04, 0.09)	-0.02 (-0.05, 0.01) .28
	BPD/DS	0.02 (0.02, 0.03)	0.04 (0.02, 0.06)	
% TBA, mean (95% CI)	RYGB	2.5 (1.5, 3.5)	2.2 (1.5, 2.9)	-1.4 (-2.2, -0.6) .001
	BPD/DS	1.8 (1.1, 2.4)	0.7 (0.3, 1.1)	
GUDCA				
μmol/L, mean (95% CI)	RYGB	0.10 (0.07, 0.14)	0.09 (0.03, 0.15)	0.09 (-0.04, 0.2) .18
	BPD/DS	0.07 (0.05, 0.09)	0.18 (0.07, 0.29)	
% TBA, mean (95% CI)	RYGB	4.9 (3.8, 5.9)	2.2 (1.4, 3.1)	-0.1 (-1.2, 0.9) .82
	BPD/DS	4.5 (3.5, 5.6)	2.2 (1.4, 2.9)	
TUDCA				
μmol/L, mean (95% CI)	RYGB	0.02 (0.01, 0.02)	0.02 (0.02, 0.02)	-0.001 (-0.006, 0.005) .78
	BPD/DS	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	
% TBA, mean (95% CI)	RYGB	1.1 (0.7, 1.5)	1.0 (0.5, 1.5)	-0.6 (-1.1, 0.002) .05
	BPD/DS	1.5 (1.1, 1.8)	0.4 (0.2,	

			0.7)		
GLCA					
μmol/L, mean (95% CI)	RYGB	0.06 (0.04, 0.08)	0.08 (0.06, 0.10)		
	BPD/DS	0.09 (0.07, 0.11)	0.09 (0.07, 0.11)		
% TBA, mean (95% CI)	RYGB	3.3 (1.9, 4.7)	3.4 (1.8, 4.9)	-1.2 (-3.4, 1.0)	.28
	BPD/DS	6.7 (5.0, 8.3)	2.2 (0.9, 3.5)		
TLCA					
μmol/L, mean (95% CI)	RYGB	0.07 (0.05, 0.10)	0.06 (0.04, 0.08)		
	BPD/DS	0.08 (0.06, 0.10)	0.09 (0.07, 0.11)		
% TBA, mean (95% CI)	RYGB	4.2 (2.4, 6.0)	2.7 (1.5, 3.8)	0.1 (-1.8, 2.0)	.92
	BPD/DS	5.9 (3.9, 7.8)	2.5 (1.0, 4.0)		

Abbreviations: RYGB, Roux-en-Y gastric bypass; BPD/DS, biliopancreatic diversion with duodenal switch; Preop, preoperatively; TBA, total bile acids; CA, cholic acid; CDCA, chenodeoxycholic acid; GCA, glycocholic acid; TCA, taurocholic acid; GCDCA, glycochenodeoxycholic acid; TCDC, taurochenodeoxycholic acid; DCA, deoxycholic acid; UDCA, ursodeoxycholic acid; LCA, lithocholic acid; GDCA, glycodeoxycholic acid; TDCA, taurodeoxycholic acid; GUDCA, glyoursodeoxycholic acid; TUDCA, tauroursodeoxycholic acid; GLCA, glycolithocholic acid; TLCA, tauroolithocholic acid.

^aFrom multiple regression with the 5 y value as dependent variable and procedure and preoperative value as independent variable.

The lowest area of detection for the individual bile acids: 0.05 μmol/L (TUDCA), 0.06 μmol/L (GUDCA), 0.07 μmol/L (CDCA, TCA, TCDC, UDCA, TDCA), 0.08 μmol/L (DCA), 0.10 μmol/L (GCA) 0.14 (GDCA), 0.16 μmol/L (GCDCA, LCA), 0.17 μmol/L (GLCA, TLCA).

Random imputation (between 0 and lowest area of detection) was used for measurements below the lowest area of detection.

Table 4. Correlation analyses of fasting serum concentrations of total bile acids and BMI, fasting serum lipids and measures of glucose metabolism at 5 years

	Spearman's Rho ^a	95% CI	P value
5y measurements	Total bile acid concentrations (n=43)		
Body mass index (kg/m ²)	-0.31	-0.56, -0.01	.042
Body mass index change (5y-B)	-0.35	-0.59, -0.06	.023
Body weight, kg	-0.26	-0.52, 0.04	.09
Body weight change (5y-B), kg	-0.39	-0.62, -0.10	.010
Body weight change (5y-B), %	-0.35	-0.56, -0.06	.021
Total cholesterol, mg/dL	-0.33	-0.57, -0.03	.036
LDL-C, mg/dL	-0.28	-0.54, 0.02	.08
HDL-C, mg/dL	-0.09	-0.39, 0.21	.56
Triglycerides, mg/dL	-0.20	-0.47, 0.11	.21
Glucose, mg/dL	-0.17	-0.45, 0.14	.28
HbA1c, %	-0.12	-0.41, 0.19	.46
C-peptide, ng/mL	-0.19	-0.46, 0.12	.24
Insulin, μ IU/mL	-0.30	-0.55, 0.00	.05
Proinsulin / insulin ratio	0.01	-0.38, 0.39	.93
HOMA-IR	-0.29	-0.54, 0.01	.06
Change from baseline to 5y^b	Change in total bile acid Concentrations^b (n=39)		
Body mass index (kg/m ²)	-0.30	-0.56, 0.02	.06
Body weight (kg)	-0.35	-0.60, -0.04	.041
Body weight (%)	-0.31	-0.57, 0.01	.06
Total cholesterol, mg/dL	-0.29	-0.55, 0.03	.08
LDL-C,	-0.31	-0.57, 0.01	.06
HDL-C, mg/dL	-0.06	-0.37, 0.26	.73
Triglycerides, mg/dL	0.05	-0.36, 0.27	.77
Glucose, mg/dL	0.03	-0.30, 0.34	.87
C-peptide, ng/mL	0.09	-0.23, 0.39	.59
Insulin, μ IU/mL	0.27	-0.03, 0.53	.12
Proinsulin / insulin ratio	0.14	-0.18, 0.44	.43
HOMA-IR	0.22	-0.10, 0.50	.21

Abbreviations: BMI, body mass index; LDL-cholesterol, low-density lipoprotein cholesterol; HDL-cholesterol, high-density lipoprotein cholesterol; HbA1c, glycated hemoglobin A1c, HOMA-IR, homeostatic model assessment - insulin resistance.

Correlation analyses were performed with both surgical groups combined and with values after cholecystectomy excluded.

^a11 patients with cholecystectomy at 5 years were excluded from all correlation analyses.

^b5y minus baseline measurements.

Figure 1. Total bile acid concentrations during 5 years of RYGB and BPD/DS

Abbreviations: RYGB, Roux-en-Y gastric bypass; BPD/DS, biliopancreatic diversion with duodenal switch; TBA, total bile acids; GB, gastric bypass; DS, duodenal switch.

Fasting serum concentrations of total bile acids from each individual measured up to 5 years after surgery. Circles represent patients with the gall bladder in situ, while squares represent patients with cholecystectomy. Horizontal black lines are observed mean values for the surgical group at each time point.